PDF(229 KB)
From Cell States to Spatial Ecotypes: Spatial Organization as an Independent Explanatory Layer of Immunotherapy Resistance
Lin Chen¹, Yiran Zhao², Wei Zhang², David K. Sterling³
Cancer Immuno Perspectives ›› 2026, Vol. 1 ›› Issue (1) : 29-45.
PDF(229 KB)
PDF(229 KB)
From Cell States to Spatial Ecotypes: Spatial Organization as an Independent Explanatory Layer of Immunotherapy Resistance
Lin Chen¹, Yiran Zhao², Wei Zhang², David K. Sterling³*
Immunotherapy resistance is still largely explained through cell-state inventories—PD-L1 expression, tumor mutational burden, and CD8⁺ T-cell infiltration—yet these markers consistently fail to capture how resistance actually operates. This narrative review argues that the explanatory limitation is not merely technical but reflects a level mismatch: isolated cell types and transcriptional states describe which participants are present, not how they are spatially organized to produce functional consequences. Evidence from bladder, renal, esophageal, lung, and breast cancers shows that abundance and function are mediated by spatial organization: CD8⁺ T cells may be present but confined to peritumoral or stromal compartments, and the same macrophage or fibroblast state may be suppressive only when positioned at a specific interface. We synthesize this evidence through the concept of the spatial ecotype—a spatially dependent multicellular ecosystem with reproducible transcriptional and functional properties—and distinguish it from cell neighborhoods and cell states. Cross-cancer analyses identify a limited set of recurrent spatial immune archetypes, suggesting conserved organizing principles rather than cancer-specific configurations. We then argue that spatial order constitutes a parallel and irreplaceable explanatory layer of resistance, operating through physical accessibility, metabolic compartmentalization, and functional contact, with emergent properties not reducible to cell-state composition. Translationally, spatial configurations are moving from descriptive features toward trial enrichment criteria, but the evidence remains at the prognostic and predictive level. Four gaps—causal status, standardization, longitudinal dynamics, and prospective decision-level evidence—define the boundaries of the current paradigm shift.
spatial ecotype / immunotherapy resistance / tumor microenvironment / spatial transcriptomics / immune exclusion / cell state / spatial immune archetypes / immune checkpoint blockade
/
| 〈 |
|
〉 |